_id
6915ed00bc934aba376b1dc2
Ticker
RCUS
Name
Arcus Biosciences Inc
Exchange
NYSE
Address
3928 Point Eden Way, Hayward, CA, United States, 94545
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.arcusbio.com
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Last Close
25.14
Volume
2581884
Current Price
21.53
Change
-14.359586316626888
Last Updated
2025-12-03T12:47:20.582Z
Image
-
Ipo Date
2018-03-15T00:00:00.000Z
Market Cap
3146416640
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.4615
Target Price
33.2222
Strong Buy
8
Buy
3
Hold
2
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
26000000
Cost Of Revenue
2000000
Gross Profit
24000000
Operating Expenses
166000000
Operating Income
-142000000
Interest Expense
3000000
Pretax Income
-135000000
Net Income
-135000000
Eps
-1.267605633802817
Dividends Per Share
-
Shares Outstanding
123728536
Income Tax Expense
-
EBITDA
-130000000
Operating Margin
-546.1538461538462
Total Other Income Expense Net
7000000
Cash
238000000
Short Term Investments
593000000
Receivables
14000000
Inventories
-
Total Current Assets
857000000
Property Plant Equipment
42000000
Total Assets
974000000
Payables
42000000
Short Term Debt
13000000
Long Term Debt
98000000
Total Liabilities
538000000
Equity
436000000
Depreciation
2000000
Change In Working Capital
21000000
Cash From Operations
-97000000
Capital Expenditures
0
Cash From Investing
79000000
Cash From Financing
8000000
Net Change In Cash
-10000000
PE
-
PB
5.2590481651376155
ROE
-30.963302752293576
ROA
-13.860369609856264
FCF
-97000000
Fcf Percent
-3.730769230769231
Piotroski FScore
1
Health Score
20
Deep Value Investing Score
2
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
1.5
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
1
Quality Investing Score
2
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
26000000
Quarters > 0 > income Statement > cost Of Revenue
2000000
Quarters > 0 > income Statement > gross Profit
24000000
Quarters > 0 > income Statement > operating Expenses
166000000
Quarters > 0 > income Statement > operating Income
-142000000
Quarters > 0 > income Statement > interest Expense
3000000
Quarters > 0 > income Statement > pretax Income
-135000000
Quarters > 0 > income Statement > net Income
-135000000
Quarters > 0 > income Statement > eps
-1.267605633802817
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
106500000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-130000000
Quarters > 0 > income Statement > operating Margin
-546.1538461538462
Quarters > 0 > income Statement > total Other Income Expense Net
7000000
Quarters > 0 > balance Sheet > cash
238000000
Quarters > 0 > balance Sheet > short Term Investments
593000000
Quarters > 0 > balance Sheet > receivables
14000000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
857000000
Quarters > 0 > balance Sheet > property Plant Equipment
42000000
Quarters > 0 > balance Sheet > total Assets
974000000
Quarters > 0 > balance Sheet > payables
42000000
Quarters > 0 > balance Sheet > short Term Debt
13000000
Quarters > 0 > balance Sheet > long Term Debt
98000000
Quarters > 0 > balance Sheet > total Liabilities
538000000
Quarters > 0 > balance Sheet > equity
436000000
Quarters > 0 > cash Flow > net Income
-135000000
Quarters > 0 > cash Flow > depreciation
2000000
Quarters > 0 > cash Flow > change In Working Capital
21000000
Quarters > 0 > cash Flow > cash From Operations
-97000000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
79000000
Quarters > 0 > cash Flow > cash From Financing
8000000
Quarters > 0 > cash Flow > net Change In Cash
-10000000
Quarters > 0 > ratios > PE
-1.267605633802817
Quarters > 0 > ratios > PB
5.2590481651376155
Quarters > 0 > ratios > ROE
-30.963302752293576
Quarters > 0 > ratios > ROA
-13.860369609856264
Quarters > 0 > ratios > FCF
-97000000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-3.730769230769231
Quarters > 0 > health Score
20
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
160000000
Quarters > 1 > income Statement > cost Of Revenue
2000000
Quarters > 1 > income Statement > gross Profit
160000000
Quarters > 1 > income Statement > operating Expenses
168000000
Quarters > 1 > income Statement > operating Income
-8000000
Quarters > 1 > income Statement > interest Expense
2000000
Quarters > 1 > income Statement > pretax Income
-8000000
Quarters > 1 > income Statement > net Income
-8000000
Quarters > 1 > income Statement > eps
-0.07511737089201878
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
106500000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
4000000
Quarters > 1 > income Statement > operating Margin
-5
Quarters > 1 > income Statement > total Other Income Expense Net
8000000
Quarters > 1 > balance Sheet > cash
248000000
Quarters > 1 > balance Sheet > short Term Investments
663000000
Quarters > 1 > balance Sheet > receivables
20000000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
946000000
Quarters > 1 > balance Sheet > property Plant Equipment
44000000
Quarters > 1 > balance Sheet > total Assets
1075000000
Quarters > 1 > balance Sheet > payables
29000000
Quarters > 1 > balance Sheet > short Term Debt
12000000
Quarters > 1 > balance Sheet > long Term Debt
97000000
Quarters > 1 > balance Sheet > total Liabilities
526000000
Quarters > 1 > balance Sheet > equity
549000000
Quarters > 1 > cash Flow > net Income
0
Quarters > 1 > cash Flow > depreciation
2000000
Quarters > 1 > cash Flow > change In Working Capital
-148000000
Quarters > 1 > cash Flow > cash From Operations
-133000000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
137000000
Quarters > 1 > cash Flow > cash From Financing
52000000
Quarters > 1 > cash Flow > net Change In Cash
56000000
Quarters > 1 > ratios > PE
-0.07511737089201878
Quarters > 1 > ratios > PB
4.176584699453552
Quarters > 1 > ratios > ROE
-1.4571948998178506
Quarters > 1 > ratios > ROA
-0.7441860465116279
Quarters > 1 > ratios > FCF
-133000000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-0.83125
Quarters > 1 > health Score
25
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
28000000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
28000000
Quarters > 2 > income Statement > operating Expenses
150000000
Quarters > 2 > income Statement > operating Income
-122000000
Quarters > 2 > income Statement > interest Expense
1000000
Quarters > 2 > income Statement > pretax Income
-112000000
Quarters > 2 > income Statement > net Income
-112000000
Quarters > 2 > income Statement > eps
-1.1382113821138211
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
98400000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-108000000
Quarters > 2 > income Statement > operating Margin
-435.71428571428567
Quarters > 2 > income Statement > total Other Income Expense Net
10000000
Quarters > 2 > balance Sheet > cash
192000000
Quarters > 2 > balance Sheet > short Term Investments
805000000
Quarters > 2 > balance Sheet > receivables
21000000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
1031000000
Quarters > 2 > balance Sheet > property Plant Equipment
46000000
Quarters > 2 > balance Sheet > total Assets
1156000000
Quarters > 2 > balance Sheet > payables
22000000
Quarters > 2 > balance Sheet > short Term Debt
12000000
Quarters > 2 > balance Sheet > long Term Debt
48000000
Quarters > 2 > balance Sheet > total Liabilities
625000000
Quarters > 2 > balance Sheet > equity
531000000
Quarters > 2 > cash Flow > net Income
-112000000
Quarters > 2 > cash Flow > depreciation
3000000
Quarters > 2 > cash Flow > change In Working Capital
-37000000
Quarters > 2 > cash Flow > cash From Operations
-132000000
Quarters > 2 > cash Flow > capital Expenditures
1000000
Quarters > 2 > cash Flow > cash From Investing
32000000
Quarters > 2 > cash Flow > cash From Financing
142000000
Quarters > 2 > cash Flow > net Change In Cash
42000000
Quarters > 2 > ratios > PE
-1.1382113821138211
Quarters > 2 > ratios > PB
3.9897401129943506
Quarters > 2 > ratios > ROE
-21.092278719397363
Quarters > 2 > ratios > ROA
-9.688581314878892
Quarters > 2 > ratios > FCF
-133000000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-4.75
Quarters > 2 > health Score
19
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
26000000
Quarters > 3 > income Statement > cost Of Revenue
3000000
Quarters > 3 > income Statement > gross Profit
26000000
Quarters > 3 > income Statement > operating Expenses
129000000
Quarters > 3 > income Statement > operating Income
-103000000
Quarters > 3 > income Statement > interest Expense
2000000
Quarters > 3 > income Statement > pretax Income
-94000000
Quarters > 3 > income Statement > net Income
-94000000
Quarters > 3 > income Statement > eps
-1.025081788440567
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
91700000
Quarters > 3 > income Statement > income Tax Expense
1000000
Quarters > 3 > income Statement > EBITDA
-89000000
Quarters > 3 > income Statement > operating Margin
-396.1538461538462
Quarters > 3 > income Statement > total Other Income Expense Net
9000000
Quarters > 3 > balance Sheet > cash
150000000
Quarters > 3 > balance Sheet > short Term Investments
828000000
Quarters > 3 > balance Sheet > receivables
25000000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1016000000
Quarters > 3 > balance Sheet > property Plant Equipment
47000000
Quarters > 3 > balance Sheet > total Assets
1150000000
Quarters > 3 > balance Sheet > payables
18000000
Quarters > 3 > balance Sheet > short Term Debt
12000000
Quarters > 3 > balance Sheet > long Term Debt
48000000
Quarters > 3 > balance Sheet > total Liabilities
665000000
Quarters > 3 > balance Sheet > equity
485000000
Quarters > 3 > cash Flow > net Income
-94000000
Quarters > 3 > cash Flow > depreciation
3000000
Quarters > 3 > cash Flow > change In Working Capital
-23000000
Quarters > 3 > cash Flow > cash From Operations
-100000000
Quarters > 3 > cash Flow > capital Expenditures
1000000
Quarters > 3 > cash Flow > cash From Investing
51000000
Quarters > 3 > cash Flow > cash From Financing
-2000000
Quarters > 3 > cash Flow > net Change In Cash
-51000000
Quarters > 3 > ratios > PE
-1.025081788440567
Quarters > 3 > ratios > PB
4.070723711340206
Quarters > 3 > ratios > ROE
-19.381443298969074
Quarters > 3 > ratios > ROA
-8.17391304347826
Quarters > 3 > ratios > FCF
-101000000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-3.8846153846153846
Quarters > 3 > health Score
19
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
258000000
Annuals > 0 > income Statement > cost Of Revenue
10000000
Annuals > 0 > income Statement > gross Profit
258000000
Annuals > 0 > income Statement > operating Expenses
588000000
Annuals > 0 > income Statement > operating Income
-330000000
Annuals > 0 > income Statement > interest Expense
4000000
Annuals > 0 > income Statement > pretax Income
-283000000
Annuals > 0 > income Statement > net Income
-283000000
Annuals > 0 > income Statement > eps
-3.1409544950055492
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
90100000
Annuals > 0 > income Statement > income Tax Expense
1000000
Annuals > 0 > income Statement > EBITDA
-269000000
Annuals > 0 > income Statement > operating Margin
-127.90697674418605
Annuals > 0 > income Statement > total Other Income Expense Net
47000000
Annuals > 0 > balance Sheet > cash
150000000
Annuals > 0 > balance Sheet > short Term Investments
828000000
Annuals > 0 > balance Sheet > receivables
25000000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
1016000000
Annuals > 0 > balance Sheet > property Plant Equipment
47000000
Annuals > 0 > balance Sheet > total Assets
1150000000
Annuals > 0 > balance Sheet > payables
18000000
Annuals > 0 > balance Sheet > short Term Debt
12000000
Annuals > 0 > balance Sheet > long Term Debt
48000000
Annuals > 0 > balance Sheet > total Liabilities
665000000
Annuals > 0 > balance Sheet > equity
485000000
Annuals > 0 > cash Flow > net Income
-283000000
Annuals > 0 > cash Flow > depreciation
10000000
Annuals > 0 > cash Flow > change In Working Capital
22000000
Annuals > 0 > cash Flow > cash From Operations
-170000000
Annuals > 0 > cash Flow > capital Expenditures
6000000
Annuals > 0 > cash Flow > cash From Investing
-84000000
Annuals > 0 > cash Flow > cash From Financing
277000000
Annuals > 0 > cash Flow > net Change In Cash
23000000
Annuals > 0 > ratios > PE
-3.1409544950055492
Annuals > 0 > ratios > PB
4.724212371134021
Annuals > 0 > ratios > ROE
-58.35051546391753
Annuals > 0 > ratios > ROA
-24.60869565217391
Annuals > 0 > ratios > FCF
-176000000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.6821705426356589
Annuals > 0 > health Score
19
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
117000000
Annuals > 1 > income Statement > cost Of Revenue
340000000
Annuals > 1 > income Statement > gross Profit
117000000
Annuals > 1 > income Statement > operating Expenses
457000000
Annuals > 1 > income Statement > operating Income
-340000000
Annuals > 1 > income Statement > interest Expense
2000000
Annuals > 1 > income Statement > pretax Income
-301000000
Annuals > 1 > income Statement > net Income
-307000000
Annuals > 1 > income Statement > eps
-4.148648648648648
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
74000000
Annuals > 1 > income Statement > income Tax Expense
6000000
Annuals > 1 > income Statement > EBITDA
-291000000
Annuals > 1 > income Statement > operating Margin
-290.5982905982906
Annuals > 1 > income Statement > total Other Income Expense Net
39000000
Annuals > 1 > balance Sheet > cash
127000000
Annuals > 1 > balance Sheet > short Term Investments
632000000
Annuals > 1 > balance Sheet > receivables
42000000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
831000000
Annuals > 1 > balance Sheet > property Plant Equipment
51000000
Annuals > 1 > balance Sheet > total Assets
1095000000
Annuals > 1 > balance Sheet > payables
17000000
Annuals > 1 > balance Sheet > short Term Debt
11000000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
633000000
Annuals > 1 > balance Sheet > equity
462000000
Annuals > 1 > cash Flow > net Income
-307000000
Annuals > 1 > cash Flow > depreciation
8000000
Annuals > 1 > cash Flow > change In Working Capital
-71000000
Annuals > 1 > cash Flow > cash From Operations
-306000000
Annuals > 1 > cash Flow > capital Expenditures
24000000
Annuals > 1 > cash Flow > cash From Investing
194000000
Annuals > 1 > cash Flow > cash From Financing
33000000
Annuals > 1 > cash Flow > net Change In Cash
-79000000
Annuals > 1 > ratios > PE
-4.148648648648648
Annuals > 1 > ratios > PB
4.0732034632034635
Annuals > 1 > ratios > ROE
-66.45021645021644
Annuals > 1 > ratios > ROA
-28.036529680365298
Annuals > 1 > ratios > FCF
-330000000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-2.8205128205128207
Annuals > 1 > health Score
19
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
112000000
Annuals > 2 > income Statement > cost Of Revenue
14000000
Annuals > 2 > income Statement > gross Profit
112000000
Annuals > 2 > income Statement > operating Expenses
392000000
Annuals > 2 > income Statement > operating Income
-280000000
Annuals > 2 > income Statement > interest Expense
2000000
Annuals > 2 > income Statement > pretax Income
-266000000
Annuals > 2 > income Statement > net Income
-267000000
Annuals > 2 > income Statement > eps
-3.7083333333333335
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
72000000
Annuals > 2 > income Statement > income Tax Expense
1000000
Annuals > 2 > income Statement > EBITDA
-258000000
Annuals > 2 > income Statement > operating Margin
-250
Annuals > 2 > income Statement > total Other Income Expense Net
14000000
Annuals > 2 > balance Sheet > cash
206000000
Annuals > 2 > balance Sheet > short Term Investments
803000000
Annuals > 2 > balance Sheet > receivables
43000000
Annuals > 2 > balance Sheet > inventories
-172000000
Annuals > 2 > balance Sheet > total Current Assets
1066000000
Annuals > 2 > balance Sheet > property Plant Equipment
135000000
Annuals > 2 > balance Sheet > total Assets
1345000000
Annuals > 2 > balance Sheet > payables
20000000
Annuals > 2 > balance Sheet > short Term Debt
3000000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
688000000
Annuals > 2 > balance Sheet > equity
657000000
Annuals > 2 > cash Flow > net Income
-267000000
Annuals > 2 > cash Flow > depreciation
14000000
Annuals > 2 > cash Flow > change In Working Capital
623000000
Annuals > 2 > cash Flow > cash From Operations
438000000
Annuals > 2 > cash Flow > capital Expenditures
6000000
Annuals > 2 > cash Flow > cash From Investing
-413000000
Annuals > 2 > cash Flow > cash From Financing
33000000
Annuals > 2 > cash Flow > net Change In Cash
58086000
Annuals > 2 > ratios > PE
-3.7083333333333335
Annuals > 2 > ratios > PB
2.786849315068493
Annuals > 2 > ratios > ROE
-40.63926940639269
Annuals > 2 > ratios > ROA
-19.851301115241636
Annuals > 2 > ratios > FCF
432000000
Annuals > 2 > ratios > Piotroski FScore
2
Annuals > 2 > ratios > fcf Percent
3.857142857142857
Annuals > 2 > health Score
44
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
383000000
Annuals > 3 > income Statement > cost Of Revenue
7057000
Annuals > 3 > income Statement > gross Profit
383000000
Annuals > 3 > income Statement > operating Expenses
329000000
Annuals > 3 > income Statement > operating Income
54000000
Annuals > 3 > income Statement > interest Expense
260000
Annuals > 3 > income Statement > pretax Income
55000000
Annuals > 3 > income Statement > net Income
53000000
Annuals > 3 > income Statement > eps
0.7165428532441688
Annuals > 3 > income Statement > dividends Per Share
5000000
Annuals > 3 > income Statement > shares Outstanding
73966267
Annuals > 3 > income Statement > income Tax Expense
2000000
Annuals > 3 > income Statement > EBITDA
59000000
Annuals > 3 > income Statement > operating Margin
14.099216710182768
Annuals > 3 > income Statement > total Other Income Expense Net
1000000
Annuals > 3 > balance Sheet > cash
147914000
Annuals > 3 > balance Sheet > short Term Investments
351394000
Annuals > 3 > balance Sheet > receivables
746822000
Annuals > 3 > balance Sheet > inventories
-762442000
Annuals > 3 > balance Sheet > total Current Assets
1261750000
Annuals > 3 > balance Sheet > property Plant Equipment
137423000
Annuals > 3 > balance Sheet > total Assets
1591898000
Annuals > 3 > balance Sheet > payables
10261000
Annuals > 3 > balance Sheet > short Term Debt
5100000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
750448000
Annuals > 3 > balance Sheet > equity
841450000
Annuals > 3 > cash Flow > net Income
52830000
Annuals > 3 > cash Flow > depreciation
3843000
Annuals > 3 > cash Flow > change In Working Capital
-375618000
Annuals > 3 > cash Flow > cash From Operations
-256171000
Annuals > 3 > cash Flow > capital Expenditures
26078000
Annuals > 3 > cash Flow > cash From Investing
-3868000
Annuals > 3 > cash Flow > cash From Financing
237340000
Annuals > 3 > cash Flow > net Change In Cash
-22699000
Annuals > 3 > ratios > PE
0.7165428532441688
Annuals > 3 > ratios > PB
2.2353819832550954
Annuals > 3 > ratios > ROE
6.298651137916692
Annuals > 3 > ratios > ROA
3.329359041848159
Annuals > 3 > ratios > FCF
-282249000
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-0.7369425587467363
Annuals > 3 > health Score
53
Valuation > metrics > PE
-1.267605633802817
Valuation > metrics > PB
5.2590481651376155
Valuation > final Score
27.409518348623845
Valuation > verdict
75.3% Overvalued
Profitability > metrics > ROE
-30.963302752293576
Profitability > metrics > ROA
-15.752625437572929
Profitability > metrics > Net Margin
-5.1923076923076925
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.2339449541284404
Risk > metrics > Interest Coverage
-47.333333333333336
Risk > final Score
-159
Risk > verdict
High
Liquidity > metrics > Current Ratio
15.581818181818182
Liquidity > metrics > Quick Ratio
15.581818181818182
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
38.23415300546448
Prev Valuations > 1
40.1025988700565
Prev Valuations > 2
39.292762886597934
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
32
Prev Risks > 1
-458
Prev Risks > 2
-176
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T01:05:18.912Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-25
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-1.19
Earnings History > 0 > eps Difference
1.19
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-10-28
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.27
Earnings History > 1 > eps Estimate
-1.28
Earnings History > 1 > eps Difference
0.01
Earnings History > 1 > surprise Percent
0.7813
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-06
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
0
Earnings History > 2 > eps Estimate
-1.12
Earnings History > 2 > eps Difference
1.12
Earnings History > 2 > surprise Percent
100
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-06
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-1.14
Earnings History > 3 > eps Estimate
-0.93
Earnings History > 3 > eps Difference
-0.21
Earnings History > 3 > surprise Percent
-22.5806
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-02-19
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-1.03
Earnings History > 4 > eps Estimate
-1.2031
Earnings History > 4 > eps Difference
0.1731
Earnings History > 4 > surprise Percent
14.3878
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-06
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-1
Earnings History > 5 > eps Estimate
-1.06
Earnings History > 5 > eps Difference
0.06
Earnings History > 5 > surprise Percent
5.6604
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-08
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-1.02
Earnings History > 6 > eps Estimate
-1.1
Earnings History > 6 > eps Difference
0.08
Earnings History > 6 > surprise Percent
7.2727
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-08
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
AfterMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.05
Earnings History > 7 > eps Estimate
-0.95
Earnings History > 7 > eps Difference
0.9
Earnings History > 7 > surprise Percent
94.7368
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-21
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-1.08
Earnings History > 8 > eps Estimate
-1.02
Earnings History > 8 > eps Difference
-0.06
Earnings History > 8 > surprise Percent
-5.8824
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-07
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.94
Earnings History > 9 > eps Estimate
-1.13
Earnings History > 9 > eps Difference
0.19
Earnings History > 9 > surprise Percent
16.8142
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-08-07
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
BeforeMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-1.04
Earnings History > 10 > eps Estimate
-1.1
Earnings History > 10 > eps Difference
0.06
Earnings History > 10 > surprise Percent
5.4545
Earnings History > 11 > period
2023-03-31
Earnings History > 11 > report Date
2023-05-09
Earnings History > 11 > date
2023-03-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-1.09
Earnings History > 11 > eps Estimate
-1.16
Earnings History > 11 > eps Difference
0.07
Earnings History > 11 > surprise Percent
6.0345
Earnings History > 12 > period
2022-12-31
Earnings History > 12 > report Date
2023-02-28
Earnings History > 12 > date
2022-12-31
Earnings History > 12 > before After Market
AfterMarket
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-0.93
Earnings History > 12 > eps Estimate
-1.07
Earnings History > 12 > eps Difference
0.14
Earnings History > 12 > surprise Percent
13.0841
Earnings History > 13 > period
2022-09-30
Earnings History > 13 > report Date
2022-11-02
Earnings History > 13 > date
2022-09-30
Earnings History > 13 > before After Market
AfterMarket
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-0.9
Earnings History > 13 > eps Estimate
-1.04
Earnings History > 13 > eps Difference
0.14
Earnings History > 13 > surprise Percent
13.4615
Earnings History > 14 > period
2022-06-30
Earnings History > 14 > report Date
2022-08-03
Earnings History > 14 > date
2022-06-30
Earnings History > 14 > before After Market
AfterMarket
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-0.93
Earnings History > 14 > eps Estimate
-0.94
Earnings History > 14 > eps Difference
0.01
Earnings History > 14 > surprise Percent
1.0638
Earnings History > 15 > period
2022-03-31
Earnings History > 15 > report Date
2022-05-09
Earnings History > 15 > date
2022-03-31
Earnings History > 15 > before After Market
AfterMarket
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-0.96
Earnings History > 15 > eps Estimate
-0.86
Earnings History > 15 > eps Difference
-0.1
Earnings History > 15 > surprise Percent
-11.6279
Earnings History > 16 > period
2021-12-31
Earnings History > 16 > report Date
2022-02-23
Earnings History > 16 > date
2021-12-31
Earnings History > 16 > before After Market
AfterMarket
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
3.71
Earnings History > 16 > eps Estimate
-0.74
Earnings History > 16 > eps Difference
4.45
Earnings History > 16 > surprise Percent
601.3514
Earnings History > 17 > period
2021-09-30
Earnings History > 17 > report Date
2021-11-08
Earnings History > 17 > date
2021-09-30
Earnings History > 17 > before After Market
AfterMarket
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-1.11
Earnings History > 17 > eps Estimate
-1.08
Earnings History > 17 > eps Difference
-0.03
Earnings History > 17 > surprise Percent
-2.7778
Earnings History > 18 > period
2021-06-30
Earnings History > 18 > report Date
2021-08-05
Earnings History > 18 > date
2021-06-30
Earnings History > 18 > before After Market
AfterMarket
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-1.09
Earnings History > 18 > eps Estimate
-0.87
Earnings History > 18 > eps Difference
-0.22
Earnings History > 18 > surprise Percent
-25.2874
Earnings History > 19 > period
2021-03-31
Earnings History > 19 > report Date
2021-05-05
Earnings History > 19 > date
2021-03-31
Earnings History > 19 > before After Market
AfterMarket
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-1.08
Earnings History > 19 > eps Estimate
-0.83
Earnings History > 19 > eps Difference
-0.25
Earnings History > 19 > surprise Percent
-30.1205
Earnings History > 20 > period
2020-12-31
Earnings History > 20 > report Date
2021-02-24
Earnings History > 20 > date
2020-12-31
Earnings History > 20 > before After Market
AfterMarket
Earnings History > 20 > currency
USD
Earnings History > 20 > eps Actual
-0.82
Earnings History > 20 > eps Estimate
-0.75
Earnings History > 20 > eps Difference
-0.07
Earnings History > 20 > surprise Percent
-9.3333
Earnings History > 21 > period
2020-09-30
Earnings History > 21 > report Date
2020-11-05
Earnings History > 21 > date
2020-09-30
Earnings History > 21 > before After Market
AfterMarket
Earnings History > 21 > currency
USD
Earnings History > 21 > eps Actual
0.03
Earnings History > 21 > eps Estimate
0.05
Earnings History > 21 > eps Difference
-0.02
Earnings History > 21 > surprise Percent
-40
Earnings History > 22 > period
2020-06-30
Earnings History > 22 > report Date
2020-08-06
Earnings History > 22 > date
2020-06-30
Earnings History > 22 > before After Market
AfterMarket
Earnings History > 22 > currency
USD
Earnings History > 22 > eps Actual
-0.93
Earnings History > 22 > eps Estimate
-0.61
Earnings History > 22 > eps Difference
-0.32
Earnings History > 22 > surprise Percent
-52.459
Earnings History > 23 > period
2020-03-31
Earnings History > 23 > report Date
2020-05-05
Earnings History > 23 > date
2020-03-31
Earnings History > 23 > before After Market
AfterMarket
Earnings History > 23 > currency
USD
Earnings History > 23 > eps Actual
-0.63
Earnings History > 23 > eps Estimate
-0.56
Earnings History > 23 > eps Difference
-0.07
Earnings History > 23 > surprise Percent
-12.5
Earnings History > 24 > period
2019-12-31
Earnings History > 24 > report Date
2020-03-05
Earnings History > 24 > date
2019-12-31
Earnings History > 24 > before After Market
AfterMarket
Earnings History > 24 > currency
USD
Earnings History > 24 > eps Actual
-0.38
Earnings History > 24 > eps Estimate
-0.51
Earnings History > 24 > eps Difference
0.13
Earnings History > 24 > surprise Percent
25.4902
Earnings History > 25 > period
2019-09-30
Earnings History > 25 > report Date
2019-11-05
Earnings History > 25 > date
2019-09-30
Earnings History > 25 > before After Market
AfterMarket
Earnings History > 25 > currency
USD
Earnings History > 25 > eps Actual
-0.51
Earnings History > 25 > eps Estimate
-0.49
Earnings History > 25 > eps Difference
-0.02
Earnings History > 25 > surprise Percent
-4.0816
Earnings History > 26 > period
2019-06-30
Earnings History > 26 > report Date
2019-08-06
Earnings History > 26 > date
2019-06-30
Earnings History > 26 > before After Market
AfterMarket
Earnings History > 26 > currency
USD
Earnings History > 26 > eps Actual
-0.64
Earnings History > 26 > eps Estimate
-0.4
Earnings History > 26 > eps Difference
-0.24
Earnings History > 26 > surprise Percent
-60
Earnings History > 27 > period
2019-03-31
Earnings History > 27 > report Date
2019-05-02
Earnings History > 27 > date
2019-03-31
Earnings History > 27 > before After Market
BeforeMarket
Earnings History > 27 > currency
USD
Earnings History > 27 > eps Actual
-0.41
Earnings History > 27 > eps Estimate
-0.35
Earnings History > 27 > eps Difference
-0.06
Earnings History > 27 > surprise Percent
-17.1429
Earnings History > 28 > period
2018-12-31
Earnings History > 28 > report Date
2019-03-05
Earnings History > 28 > date
2018-12-31
Earnings History > 28 > before After Market
AfterMarket
Earnings History > 28 > currency
USD
Earnings History > 28 > eps Actual
-0.28
Earnings History > 28 > eps Estimate
-0.44
Earnings History > 28 > eps Difference
0.16
Earnings History > 28 > surprise Percent
36.3636
Earnings History > 29 > period
2018-09-30
Earnings History > 29 > report Date
2018-11-08
Earnings History > 29 > date
2018-09-30
Earnings History > 29 > before After Market
AfterMarket
Earnings History > 29 > currency
USD
Earnings History > 29 > eps Actual
-0.25
Earnings History > 29 > eps Estimate
-0.38
Earnings History > 29 > eps Difference
0.13
Earnings History > 29 > surprise Percent
34.2105
Earnings History > 30 > period
2018-06-30
Earnings History > 30 > report Date
2018-08-06
Earnings History > 30 > date
2018-06-30
Earnings History > 30 > before After Market
AfterMarket
Earnings History > 30 > currency
USD
Earnings History > 30 > eps Actual
-0.32
Earnings History > 30 > eps Estimate
-0.4
Earnings History > 30 > eps Difference
0.08
Earnings History > 30 > surprise Percent
20
Earnings History > 31 > period
2018-03-31
Earnings History > 31 > report Date
2018-05-09
Earnings History > 31 > date
2018-03-31
Earnings History > 31 > before After Market
AfterMarket
Earnings History > 31 > currency
USD
Earnings History > 31 > eps Actual
-1.37
Earnings History > 31 > eps Estimate
-0.88
Earnings History > 31 > eps Difference
-0.49
Earnings History > 31 > surprise Percent
-55.6818
Earnings History > 32 > period
2017-12-31
Earnings History > 32 > report Date
2018-03-16
Earnings History > 32 > date
2017-12-31
Earnings History > 32 > before After Market
AfterMarket
Earnings History > 32 > currency
USD
Earnings History > 32 > eps Actual
-0.38
Earnings History > 32 > eps Estimate
0
Earnings History > 32 > eps Difference
-0.38
Earnings History > 32 > surprise Percent
-
Earnings History > 33 > period
2017-03-31
Earnings History > 33 > report Date
2017-05-04
Earnings History > 33 > date
2017-03-31
Earnings History > 33 > before After Market
-
Earnings History > 33 > currency
USD
Earnings History > 33 > eps Actual
-0.17
Earnings History > 33 > eps Estimate
0
Earnings History > 33 > eps Difference
-0.17
Earnings History > 33 > surprise Percent
-
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ATruist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $30 富途牛牛
Read more →RCUS Stock Down on Decision to Discontinue GILD Partnered Study Yahoo Finance
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$33.2222
Analyst Picks
Strong Buy
8
Buy
3
Hold
2
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 67.00% of the total shares of Arcus Biosciences Inc
1.
BlackRock Inc(10.7656%)
since
2025/06/30
2.
Vanguard Group Inc(6.1601%)
since
2025/06/30
3.
Point72 Asset Management, L.P.(5.6061%)
since
2025/06/30
4.
iShares Core S&P Small-Cap ETF(3.7878%)
since
2025/08/31
5.
Woodline Partners LP(3.7583%)
since
2025/06/30
6.
Suvretta Capital Management, LLC(3.466%)
since
2025/06/30
7.
State Street Corp(3.4114%)
since
2025/06/30
8.
FMR Inc(2.4178%)
since
2025/06/30
9.
Vanguard Total Stock Mkt Idx Inv(1.9808%)
since
2025/07/31
10.
iShares Russell 2000 ETF(1.5626%)
since
2025/08/31
11.
Dimensional Fund Advisors, Inc.(1.5596%)
since
2025/06/30
12.
Siren, L.L.C.(1.5147%)
since
2025/06/30
13.
Geode Capital Management, LLC(1.4999%)
since
2025/06/30
14.
Morgan Stanley - Brokerage Accounts(1.381%)
since
2025/06/30
15.
BNP Paribas Investment Partners SA(1.3114%)
since
2025/06/30
16.
Sofinnova Ventures(1.1425%)
since
2025/06/30
17.
SPDR® S&P Biotech ETF(1.1297%)
since
2025/08/31
18.
Fidelity Select Biotechnology(1.1164%)
since
2025/07/31
19.
RA Capital Management, LLC(1.0677%)
since
2025/06/30
20.
Wellington Management Company LLP(0.8795%)
since
2025/06/30
21.
Fidelity Select Pharmaceuticals Port(0.8019%)
since
2025/07/31
22.
Jacobs Levy Equity Management, Inc.(0.7566%)
since
2025/06/30
23.
BNP Paribas US Small Cap ClassicC(0.7426%)
since
2025/07/31
24.
Millennium Management LLC(0.733%)
since
2025/06/30
25.
Charles Schwab Investment Management Inc(0.7298%)
since
2025/06/30
26.
Vanguard Small Cap Index(0.7241%)
since
2025/07/31
27.
Vanguard Institutional Extnd Mkt Idx Tr(0.7013%)
since
2025/07/31
28.
Northern Trust Corp(0.6495%)
since
2025/06/30
29.
Fidelity Small Cap Index(0.649%)
since
2025/06/30
30.
Goldman Sachs Group Inc(0.6089%)
since
2025/06/30
31.
BNP Paribas Health Cr Innovtr Cl Cap(0.573%)
since
2025/07/31
32.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.5549%)
since
2025/08/29
33.
iShares S&P Small-Cap 600 Growth ETF(0.5469%)
since
2025/08/31
34.
Merchfondo FI(0.4604%)
since
2025/08/31
35.
iShares Russell 2000 Growth ETF(0.4185%)
since
2025/08/31
36.
Vanguard Small Cap Growth Index Inv(0.4069%)
since
2025/07/31
37.
iShares Biotechnology ETF(0.3599%)
since
2025/08/31
38.
Vanguard Explorer Inv(0.3568%)
since
2025/06/30
39.
Macquarie Healthcare I(0.3562%)
since
2025/07/31
40.
Fidelity Extended Market Index(0.3471%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-1.19
Date
2025-09-30
EPS Actual
-1.27
EPS Estimate
-1.28
EPS Difference
0.01
Surprise Percent
0.7813%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.